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ABSTRACT 
Multiple Drug Resistance is one of the main challenges researchers face when 
developing effective chemotherapy drugs in most cancers. Recent studies have shown 
that in neuroblastoma, BRG1 gene is active as a pro-oncogenic factor and reducing 
BRG1 levels by short hairpin RNA decreased neuroblastoma cell proliferation. In a 
previous study, BRG1 was shown to regulate drug transporter gene expression in 
response to chemotherapy drug treatment in triple negative breast cancer cells. In this 
study, we explored the relationship between BRG1 and drug transporters to elucidate 
the effect of BRG1 silencing on drug resistant neuroblastoma cells treated with 
chemotherapy drugs. The results support the hypothesis that targeting BRG1 may 
increase chemo sensitivity in drug resistant neuroblastoma cells.  
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INTRODUCTION 
 
Neuroblastoma (NB) refers to a cancerous disease state in the immature nerve tissue 
(neuroblasts). It often originates in the neural crest in the adrenal gland, but rarely occur in other 
sites of the sympathetic chain ganglia from the neck to the coccyx1. Typically, this disease is 
diagnosed in infancy and can even be detected as early as the fetal stage by ultrasounds, though 
often metastasized by the time it is detected2.  It is the most common solid tumor found in infants, 
resulting in about 15% of death every year3. NB varies in the potential clinical outcomes, ranging 
from spontaneous remission to treatment resistant metastatic tumors3. Of the high-risk patients who 
seek treatment in the form of intense rounds of chemotherapy, radiation therapy and bone marrow 
transplant, about 60-70% of these neuroblastoma cases are not cured. This is because metastatic 
tumors and relapsed tumors gain resistance to multiple drugs, making it almost impossible to cure 
using currently known treatments. There are multiple mechanisms that confer such strong therapy 
resistance to NB, many of which are not yet known.  
 
Drug Transporters Responsible for Multidrug Resistance  
Typically, when cancer cells no longer respond to a specific drug, a combination of various 
drugs that act via different mechanisms will be used. However, cancer cells have the ability to 
develop resistance to multiple drugs with different mechanisms, a phenomena called multidrug 
resistance (MDR). This presents a challenge when attempting treatment of cancer by solely 
depending on drug efficacy4. Studies aimed to understand the molecular basis of MDR found that 
active extrusion of drugs from cancer cells is one of the most common mechanisms employed in 
developing drug resistance5. Many of these systems that carry out drug extrusion harness energy 
from ATP hydrolysis to transport molecules across cell membranes. The ATP-binding Cassette 
(ABC) family ATPases are the most well characterized drug transporters. These ABC transporters 
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have two transmembrane domains and two nucleotide binding domains which are found on the 
cytoplasmic membrane surface where the ABC signature sequence is located as seen in Figure 1 
below5. 
Figure 1 
 
From: Mechanisms of multidrug transporters FEMS Microbiol Rev. 1997;21(1):55-84. 
doi:10.1111/j.1574-6976.1997.tb00345 
 
 
In human cancer cells, P-glycoprotein (P-gp or MDR1) encoded by ABCB1 gene, multidrug 
resistance proteins (MRPs) encoded by ABC C family members and ABCG2 are some of the main 
ABC transporters are known to confer multidrug resistance6,7. The MRP genes include MRP1 which 
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is an integral membrane protein which a core that is similar to Mdr-1, it is commonly expressed in 
various cells including cerebral cells. MRP4 and MRP5 are also expressed in various cells types at 
lower levels and are encoded by ABCC4 and ABCC5 respectively. MDR1is a protein that functions 
as a drug transport pump located in the blood-brain barrier shuttling various drugs from the brain 
back into the blood.  The MDR1 gene is located on chromosome 7 and also referred to as ABCB18. 
ABCG2 is abundantly expressed in placenta, intestine and stem cells. It is a half-transporter that 
provides resistance to a variety of chemotherapeutic drugs including mitoxantrone, bisantrene and 
anthracyclines such as doxorubicin9. ABCG2 is essential for stem cell differentiation and under 
normal conditions, and is also found in the blood-brain barrier where it is responsible for disposing 
of toxins found in cells7. However, it is still unclear to researchers which particular cancers need 
these transporters in an effort to identify them as clinical targets for possible therapies7. In this 
study, I surveyed the expression of these transporter genes in drug resistant CHLA-20 and SK-N-
BE(2) cell lines and measured the chemotherapy drug efficacy in these cells with or without  BRG1 
knockdown.  
 
BRG1 AND NB 
	
 
 
Adapted from: Imbalzano, 2017 
 
 
Figure 2.  Domain Structure of BRG1  
The domains that are conserved are labelled and the numbers across the top represent amino acids  
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When DNA is tightly packed, it is not accessible for transcription. The mammalian 
SWI/SNF complex is a chromatin remodeling complex that uses the energy of ATP hydrolysis to 
open up the tightly packed DNA sequences for transcription.  The mammalian SWI/SNF complex 
contains two mutual exclusive ATPases, BRG1 encoded by SMARCA4 or BRM encoded by 
SMARCA2. Many cellular processes including cell proliferation, transcription, immunological 
responses, early development of an embryo, cancer and tissue differentiation are regulated by the 
SWI/SNF complex. As seen above, BRG1 is a multi-domain protein that shares about 86% 
similarity with BRM, another ATPase subunit. BRG1 has both DNA and protein interaction 
modules as seen in Figure 2. In eukaryotic cells, DNA is not present as a linear double helix. Instead, 
DNA is tightly coiled around histones to form nucleosomes, and nucleosomes pack together to 
form chromatin.  
While BRG1 was previously identified as a tumor suppressor in some cancers10, 
overexpression has also been associated with poor outcomes for patients and upregulated in 
multiple carcinomas including melanoma11, pancreatic cancer12, glioma13, prostate carcinoma14,15 and 
breast cancer16. A recent study suggests that BRG1 may, in fact, be necessary for proliferation of NB 
cells and BRG1 gene silencing can interrupt cell proliferation and tumor growth. BRG1’s role 
proved to be essential in neuroblastoma; knockdown led to reduction in cell growth, apoptotic cell 
death and slowed tumor progression in mouse xenograft model3. In breast cancer, it was shown that 
BRG1 was responsible for the upregulation of de-novo fatty acid synthesis in an effort to meet the 
demand of cancer cell proliferation17. Further, BRG1 is required to up-regulate drug transporter 
gene expression to facilitate cancer cells survival under chemotherapy treatment. Based on its 
essential roles in neuroblastoma and breast cancer, we hypothesize that BRG1 may involve in 
mediating chemotherapy resistance in neuroblastoma. 
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RESULTS 
1. Survey drug transporter gene expression  
We used four pairs of neuroblastoma cell lines that derived from patients’ pretreated tumors 
and post-treatment but relapsed tumors.  The CHLA-15, SK-N-BE(1), SMS-KCN and SMS-
KAN pretreated cell lines were paired with CHLA-20, SK-N-BE(2), SMS-KCNR and SMS-
KANR relapsed tumor cell lines respectively (Appendix). The matched pair of cell lines were 
derived from the same patient. We surveyed the transporter gene expression by RT-qPCR in 
these lines. Relative gene expression was measured by comparing the expression of 
transporter genes to the house keeping gene GAPDH and the fold change was presented as 
the relative gene expression in relapsed lines to pre-treatment lines. In figure 3, it is 
important to note that there is an overall increase in the expression of these drug 
transporters in the relapsed tumor cell lines. 
 
Figure 3. Drug Transporters Are Up-regulated in Relapsed NB  
2. Chemotherapy drug treatment induced the expression of transporter genes 
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In pre-treated neuroblastoma line CHLA-15 responded to etoposide treatment with an IC90 at 
0.2 ng/mL. However, in CHLA-20 relapsed tumor cells there is a development of resistance to 
etoposide (ETOP) and effective dose of etoposide increased to 691 ng/mL. Etoposide 
treatment at 350 ng/mL in CHLA-20 dose markedly increased the expression of major drug 
transporters such as ABCB1, ABCC1, ABCC3, ABCC4, ABCC5, ABCC11 and ABCG1 (Figure 
3). It is worth noting that in addition to an increase in some drug transporter expression, BRG1 
expression was also increased in the presence of this chemotherapy drug. In cells that normally 
express P-gp, there is typically an increase in P-gp expression following chemotherapy and can 
result in multidrug resistance in some tumors24. Multidrug resistance is often acquired as a result 
of various transporters preventing several drugs from being effective, this is supported by the 
increase in other transporter mRNA levels following ETOP treatment.  
 
3. Generation of doxycycline inducible BRG1 knockdown lines in CHLA-20 and SK-N-BE(2) 
To better understand the role of BRG1 in chemotherapy resistant neuroblastoma cells, we 
engineered short hairpin RNA (shRNA) either scramble control or shRNA targeting BRG1 in 
CHLA-20 and SK-N-BE(2) cells in doxycycline inducible manner. In the absence of 
doxycycline, the shRNA which is under the control of tetracycline repressor will not be 
expressed thus there is no BRG1 knockdown effect. Only in the presence of doxycycline, the 
shRNA will be de-repressed and subsequently interfere with BRG1 expression to achieve a gene 
knockdown effect. As seen in Figure 4 below, Western blotting confirmed the successful 
knockdown of BRG1 expression in these two cell lines.  
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Figure 4. Western Blot to confirm successful BRG1 gene knockdown in shBRG1 cells 
 
4. BRG1 knockdown sensitized resistant neuroblastoma cells to chemotherapy  
To test the hypothesis that reducing BRG1 levels enhances chemotherapy efficacy, we treated 
the pre-treatment line SK-N-BE(1), post-treatment and relapsed lines SK-N-BE(2) scramble or 
SK-N-BE(2)shBRG1 with chemotherapy drug doxorubicin. SK-N-BE(1) cells are sensitive to 
doxorubicin with IC90 <0.1 ng/mL, whereas  SK-N-BE(2) cells are resistant to doxorubicin 
with IC90 at 92.3 ng/mL. As shown in Figure 6, knockdown of BRG1 significantly enhanced 
doxorubicin efficacy in the resistant cells almost to the level of pre-treatment cells. 
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Figure 5.  Etoposide drug-induced ABC transporter gene expression in neuroblastoma cell line 
CHLA-20 
 
  
 
Figure 6. Reduction of BRG1 levels in relapsed cell lines increased the chemo sensitivity of 
neuroblastoma cells to doxorubicin 
 
Research shows that BRG1 regulates some drug transporters in cancer cells which are 
responsible for chemotherapy drug trafficking4. BRG1 was discovered to be bound near the 
transcription start sites for multiple ABC transporters, suggesting that BRG1 plays a role in drug-
mediated up-regulation of these transporters4. To determine the effect that BRG1 knockdown has 
on sensitivity to drug treatment, the BRG1 gene was silenced using siRNA. Figure 6 shows that 
following BRG1 gene silencing in the relapsed tumor cell line, these formerly drug resistant cells 
now have a sensitive response to doxorubicin treatment.  
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DISCUSSION 
Multiple drug resistance has always been a challenge in cancer treatment via chemotherapy 
and many years of research have been done to develop an effective approach to overcome drug 
resistance. Over-expression of drug transporters such as MDR1 or P-gp is one of the most common 
cause of drug resistance. Therefore, these transporters became attractive target and many inhibitory 
compounds were developed over the last decades. However, these transporters also play important 
roles in normal physiology. This led to the failure of clinical trials of inhibitors directly targeting 
these transporters.  
We have shown that the expression of drug transporter genes is much higher in drug 
resistant neuroblastoma cells compared to pre-treated cells. Chemotherapy drug treatment 
significantly increased the expression of these transporters in drug resistant cells. More importantly, 
BRG1 knockdown enhances chemotherapy drug efficacy in drug resistant cells. Therefore, targeting 
BRG1could be an effective approach to overcome drug resistance in neuroblastoma. ABC 
transporters which are usually responsible for drug extrusion in various cancer cells depend on 
BRG126. This suggests that silencing BRG1 should result in a reduction of drug extrusion leading to 
decreased chemotherapeutic failure. Research has proved that BRG1 is essential in NB cells viability 
and silencing BRG1 promoted NB cells to apoptosis. Since BRG1 has been shown to involve in 
other signaling pathways such as lipogenesis, WNT signaling, and DNA repaired, it is possible that 
other mechanisms are contributed to the increased drug efficacy when BRG1 is silenced26. This 
provides a promising path into treating cancers like neuroblastomas specifically by inhibiting BRG1 
in order to return drug sensitivity to relapsed tumor cells enhancing clinical outcomes of 
chemotherapy. I conclude that these findings present the possibility that targeting BRG1 could be an 
effective way to increase the effectivity of chemotherapy drug use in treating neuroblastoma 
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patients. Though challenging, this is a promising place for further research on whether specific 
BRG1 knockdown is a reliable solution that can actually be used to treat tumors in patients. 
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MATERIALS AND METHODS 
Cell Culture 
The human neuroblastoma cell lines (CHLA-15, CHLA-20, SK-N-BE(1), SK-N-BE(2), SMS-KCN, 
SMS-KCNR, SMS-KAN, and SMS-KANR) were obtained from Childhood Cancer Repository from 
the Children’s Oncology Group Resource Library. CHLA-15 and CHLA-20 cells were grown in a 
base medium of Iscove’s Modified Dulbecco’s Medium plus the following supplements (to a final 
concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL 
transferrin, 5 ng/mL selenous acid).  SK-N-BE(1), SK-N-BE(2), SMS-KCN, SMS-KCNR, SMS-
KAN, and SMS-KANR cells were cultured in RPMI-1640 media plus 10% Fetal Bovine Serum and 
2mM L-Glutamine . Al cells Cells were cultured in 10cm dishes and incubated at 37°C in a 
humidified atmosphere of 5% CO2. 
	
 
Lentiviral mediated gene knockdown 
 
The doxycycline inducible SMART Vector scramble and shBRG1 were purchased from Dhamarcon 
Inc. The lentivirus cDNAs were produced by co-transfecting with plasmids pLP1, pLP2 and 
pVSVG (Invitrogen) into HEK293T cells. The viral supernatant was collected 48 hours after 
transfection and transduced the cells for 24 hours followed by selection in media containing 2 
ug/mL puromycin. Titers were determined and the same number of virus was used, as indicated. 
Gene knockdown was induced by incubation of cells in medium containing 1µg/mL Doxycycline 
(Sigma-Aldrich) for 72 hours.  
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Drug Treatment 
Cells were plated at 5,000 cells/per well in 96-well plates and incubated overnight before treatment 
with increasing doses of drugs for 72 hours. 
 
MTT assay 
Cell viability was measured using MTT assay. Cell viability was measured in 24 hour intervals by 
adding MTT solution (final concentration 5 µg/mL) to each well and incubated for 4 hours. After 
removal of the media, the plate was air-dried and 100 µL DMSO were added. The plate was 
incubated at room temperature for 30 min with gentle shaking. Absorbance was measured at OD540 
in a Synergy H4 Hybrid microplate reader (Bio Tek, Winooski, VT). 
 
RT-qPCR 
Total RNA was extracted from one million cells using RNeasy Plus following manufacturer’s 
instruction (Qiagen Inc., Valencia, CA). cDNA synthesis was done using SuperScript III kit 
(Invitrogen, San Diego, CA). Gene expression was measured by real time qPCR on a StepOne Plus 
realtime PCR System (Applied BioSystems, Grand Island, NY) using various primers. 
  
Statistical Analyses 
Quantitative data points represent the mean of three independent experiments performed in 
duplicates or triplicates with standard deviation (S.D). Unless indicated, statistical analysis was 
performed using GraphPad Instat two-tail P value student test (Graphpad Software, Inc., La Jolla, 
CA). The significance of the correlation between BRG1 expression and the expression of each of 
the transporter genes was determined by calculating the Pearson coefficient.  
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APPENDIX
 
 
 
 
 
CHLA-15 Cell Line Data Sheet 
 
 
Cell Line Name:        CHLA-15 
 
Disease: 
Phase of Therapy: 
Prior Therapy: 
Disease Stage: 
Source of Culture: 
Primary Tumor Site: 
Date Established: 
 
MYCN Status: 
p53 Status:  
TH expression: 
Karyotype: 
Modal No: 
 
IC90 (DIMSCAN*): 
*see reference 7 
 
 
 
Gender: 
Age: 
Race: 
 
STR Profile: 
 
Media Formulation: 
 
 
 
Growth Conditions: 
Subculturing: 
Doubling Time: 
Morphology: 
Growth Properties: 
 
Notes: 
 
 
 
Neuroblastoma 
Diagnosis 
None 
4 
Primary tumor 
 
April 1988 
 
Non-amplified 
Functional 
Expressed 
 
 
 
 CBDCA (µg/ml)         CDDP (µg/ml)         DOX (ng/ml)         ETOP (ng/ml)         L-PAM (µg/ml) 
 1.1                              0.2                1.1                 0.2    1.5 
 
CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan 
 
 
Female 
18 months 
 
 
On file at  http://strdb.cogcell.com 
 
Cells are grown in a base medium of Iscove’s Modified Dulbecco’s Medium plus the following 
supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine,  
1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid) 
 
37.0°C, 5% CO2, 20% O2 
Next page or Protocols section at  http://www.cogcell.org/protocols.php 
21 hours 
Teardrop-shaped cells with processes 
Adherent, grows as loosely attached monolayer, numerous tight clumps 
 
COGcell.org has a post-treatment cell line available from this same patient (CHLA-20) 
 
 
 
 
All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO.  Each vial label 
contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen.  All 
cell lines are validated with original patient sample by STR analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COG Cell Line & Xenograft Repository 
www.cogcell.org 
E-mail:  CellLineInfo@cogcell.org 1 / 4 
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CHLA-20 Cell Line Data Sheet 
 
 
Cell Line Name:        CHLA-20 
 
Disease: 
Phase of Therapy: 
Prior Therapy: 
Disease Stage: 
Source of Culture: 
Primary Tumor Site: 
Date Established: 
 
MYCN Status: 
p53 Status:  
TH expression: 
Karyotype: 
Modal No: 
 
IC90 (DIMSCAN*): 
*see reference 5 
 
 
 
Gender: 
Age: 
Race: 
 
STR Profile: 
 
Media Formulation: 
 
 
 
Growth Conditions: 
Subculturing: 
Doubling Time: 
Morphology: 
Growth Properties: 
 
Notes: 
 
 
 
Neuroblastoma 
Post-Chemotherapy (Progressive Disease) 
Cisplatin, cyclophosphamide, doxorubicin, teniposide 
4 
Primary tumor 
 
October 1988 
 
Non-amplified 
Functional 
Expressed 
 
 
 
 CBDCA (µg/ml)         CDDP (µg/ml)         DOX (ng/ml)         ETOP (ng/ml)         L-PAM (µg/ml) 
3.7                              1.1              497.6                691    1.3 
 
CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan 
 
 
Female 
24 months 
 
 
On file at  http://strdb.cogcell.com 
 
Cells are grown in a base medium of Iscove’s Modified Dulbecco’s Medium plus the following 
supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine,  
1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid) 
 
37.0°C, 5% CO2, 20% O2 
Next page or Protocols section at  http://www.cogcell.org/protocols.php 
28 hours 
Teardrop-shaped cells with processes 
Adherent, grows as loosely attached monolayer, numerous tight clumps 
 
COGcell.org has a diagnosis (pre-therapy) cell line available from this same patient (CHLA-15) 
 
 
 
 
 
All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO.  Each vial label 
contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen.  All 
cell lines are validated with original patient sample by STR analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COG Cell Line & Xenograft Repository 
www.cogcell.org 
E-mail:  CellLineInfo@cogcell.org 1 / 4 
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SK-N-BE(1) Cell Line Data Sheet 
 
 
Cell Line Name:        SK-N-BE(1) 
 
Disease: 
Phase of Therapy: 
Prior Therapy: 
Disease Stage: 
Source of Culture: 
Primary Tumor Site: 
Date Established: 
 
MYCN Status: 
p53 Status:  
TH expression: 
Karyotype: 
Modal No: 
 
IC90 (DIMSCAN*): 
*see reference 7 
 
 
 
Gender: 
Age: 
Race: 
 
STR Profile: 
 
Media Formulation: 
 
 
 
Growth Conditions: 
Subculturing: 
Doubling Time: 
Morphology: 
Growth Properties: 
 
Notes: 
 
 
Neuroblastoma 
Diagnosis 
None 
4 
Bone marrow 
 
June 1972 
 
Amplified 
 
Expressed 
 
46 
 
 CBDCA (µg/ml)         CDDP (µg/ml)         DOX (ng/ml)         ETOP (ng/ml)         L-PAM (µg/ml) 
           0.2                            <0.1               <0.1                158     0.8 
 
CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan 
 
 
Male 
24 months 
 
 
On file at  http://strdb.cogcell.com 
 
Cells are grown in a base medium of RPMI-1640 plus the following supplements (to a final 
concentration): 10% Fetal Bovine Serum, 2mM L-Glutamine 
 
 
37.0°C, 5% CO2, 20% O2 
Next page or Protocols section at  http://www.cogcell.org/protocols.php 
96 hours 
Neuroblasts with some attached containing occasional processes 
Adherent and suspended cells 
 
COGcell.org has a post-treatment cell line available from this same patient - SK-N-BE(2) 
 
 
 
 
 
All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO.  Each vial label 
contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen.  All 
cell lines are validated with original patient sample by STR analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COG Cell Line & Xenograft Repository 
www.cogcell.org 
E-mail:  CellLineInfo@cogcell.org 1 / 4 
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SK-N-BE(2) Cell Line Data Sheet 
 
 
Cell Line Name:        SK-N-BE(2) 
 
Disease: 
Phase of Therapy: 
Prior Therapy: 
Disease Stage: 
Source of Culture: 
Primary Tumor Site: 
Date Established: 
 
MYCN Status: 
p53 Status:  
TH expression: 
Karyotype: 
 
Modal No: 
 
IC90 (DIMSCAN*): 
*see reference 9 
 
 
 
Gender: 
Age: 
Race: 
 
STR Profile: 
 
Media Formulation: 
 
 
 
Growth Conditions: 
Subculturing: 
Doubling Time: 
Morphology: 
Growth Properties: 
 
Notes: 
 
 
 
Neuroblastoma 
Post-Chemotherapy (Progressive Disease) 
Cyclophosphamide, doxorubicin, vincristine, local irradiation 
4 
Bone marrow 
Brain 
November 1972 
 
Amplified 
Non-functional 
Expressed 
t(1;2)(p22;p21),t(3;17)(p21;q21), Monosomy (17,18), variable rearrangements involving  
chromosomes (4,6,9,10,11,and/or 20) 
44 
 
 CBDCA (µg/ml)         CDDP (µg/ml)         DOX (ng/ml)         ETOP (ng/ml)         L-PAM (µg/ml) 
           2.1                             0.2               92.3              1130     24 
 
CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan 
 
 
Male 
24 months 
 
 
On file at  http://strdb.cogcell.com 
 
Cells are grown in a base medium of RPMI-1640 plus the following supplements (to a final 
concentration): 10% Fetal Bovine Serum, 2mM L-Glutamine 
 
 
37.0°C, 5% CO2, 20% O2 
Next page or Protocols section at  http://www.cogcell.org/protocols.php 
30 hours 
Neuroblasts 
Adherent and suspended cells 
 
COGcell.org has a diagnosis (pre-therapy) cell line available from this same patient - SK-N-BE(1) 
 
 
 
All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO.  Each vial label 
contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen.  All 
cell lines are validated with original patient sample by STR analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COG Cell Line & Xenograft Repository 
www.cogcell.org 
E-mail:  CellLineInfo@cogcell.org 1 / 4 
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SMS-KCN Cell Line Data Sheet 
 
 
Cell Line Name:        SMS-KCN 
 
Disease: 
Phase of Therapy: 
Prior Therapy: 
Disease Stage: 
Source of Culture: 
Primary Tumor Site: 
Date Established: 
 
MYCN Status: 
p53 Status:  
TH expression: 
Karyotype: 
Modal No: 
 
IC90 (DIMSCAN*): 
*see reference 6 
 
 
 
Gender: 
Age: 
Race: 
 
STR Profile: 
 
Media Formulation: 
 
 
 
Growth Conditions: 
Subculturing: 
Doubling Time: 
Morphology: 
Growth Properties: 
 
Notes: 
 
 
 
Neuroblastoma 
Diagnosis 
None 
4 
Primary tumor – retroperitoneum, liver (anterior apron), lymph nodes (portal hepatis) 
Adrenal gland 
September 1979 
 
Amplified 
Functional 
Expressed 
del(1)(p34), t(17;20)(q21or22;q13) 
46 
 
 CBDCA (µg/ml)         CDDP (µg/ml)         DOX (ng/ml)         ETOP (ng/ml)         L-PAM (µg/ml) 
           1.4                             0.5               24.7                323     5.5 
 
CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan 
 
 
Male 
11 months 
Caucasian 
 
On file at  http://strdb.cogcell.com 
 
Cells are grown in a base medium of RPMI-1640 plus the following supplements (to a final 
concentration): 10% Fetal Bovine Serum, 2mM L-Glutamine 
 
 
37.0°C, 5% CO2, 20% O2 
Next page or Protocols section at  http://www.cogcell.org/protocols.php 
109 hours 
Round, teardrop-shaped neuroblasts 
Adherent and suspended cells, grow mostly in clumps 
 
COGcell.org has a post-treatment cell line available from this same patient (SMS-KCNR) 
 
 
 
 
All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO.  Each vial label 
contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen.  All 
cell lines are validated with original patient sample by STR analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COG Cell Line & Xenograft Repository 
www.cogcell.org 
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SMS-KCNR Cell Line Data Sheet 
 
 
Cell Line Name:        SMS-KCNR 
 
Disease: 
Phase of Therapy: 
Prior Therapy: 
Disease Stage: 
Source of Culture: 
Primary Tumor Site: 
Date Established: 
 
MYCN Status: 
p53 Status:  
TH expression: 
Karyotype: 
Modal No: 
 
IC90 (DIMSCAN*): 
*see reference 11 
 
 
 
Gender: 
Age: 
Race: 
 
STR Profile: 
 
Media Formulation: 
 
 
 
Growth Conditions: 
Subculturing: 
Doubling Time: 
Morphology: 
Growth Properties: 
 
Notes: 
 
 
 
Neuroblastoma 
Post-Chemotherapy (Progressive Disease) 
Doxorubicin, cyclophosphamide 
4 
Bone marrow 
Adrenal gland 
November 1979 
 
Amplified 
Functional 
Expressed 
del(1)(p34), t(17;20)(q21or22;q13), t(6;?)(q21or22;?) 
46 
 
 CBDCA (µg/ml)         CDDP (µg/ml)         DOX (ng/ml)         ETOP (ng/ml)         L-PAM (µg/ml) 
           1.9                             0.3                17                10.5     3.8 
 
CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan 
 
 
Male 
11 months 
Caucasian 
 
On file at  http://strdb.cogcell.com 
 
Cells are grown in a base medium of RPMI-1640 plus the following supplements (to a final 
concentration): 10% Fetal Bovine Serum, 2mM L-Glutamine 
 
 
37.0°C, 5% CO2, 20% O2 
Next page or Protocols section at  http://www.cogcell.org/protocols.php 
72 hours 
Round, teardrop-shaped neuroblasts 
Adherent and suspended cells, grow mostly in clumps 
 
COGcell.org has a diagnosis (pre-therapy) cell line available from this same patient (SMS-KCN) 
 
 
 
 
All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO.  Each vial label 
contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen.  All 
cell lines are validated with original patient sample by STR analysis. 
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SMS-KAN Cell Line Data Sheet 
 
 
Cell Line Name:        SMS-KAN 
 
Disease: 
Phase of Therapy: 
Prior Therapy: 
Disease Stage: 
Source of Culture: 
Primary Tumor Site: 
Date Established: 
 
MYCN Status: 
p53 Status:  
TH expression: 
Karyotype: 
Modal No: 
 
IC90 (DIMSCAN*): 
*see reference 9 
 
 
 
Gender: 
Age: 
Race: 
 
STR Profile: 
 
Media Formulation: 
 
 
 
Growth Conditions: 
Subculturing: 
Doubling Time: 
Morphology: 
Growth Properties: 
 
Notes: 
 
 
 
Neuroblastoma 
Diagnosis 
None 
4 
Primary tumor 
Pelvis 
October 1978 
 
Amplified 
  
Expressed 
del(1)(p21),del(4)(q21),del(11)(q21),del(17)(p11),del(19)(q13),t(4;10)(q21;q26),t(17;18)(q21;p11)44 
46 
 
 CBDCA (µg/ml)         CDDP (µg/ml)         DOX (ng/ml)         ETOP (ng/ml)         L-PAM (µg/ml) 
           2.2                             0.3               34.8               146     0.6 
 
CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan 
 
 
Female 
36 months 
 
 
On file at  http://strdb.cogcell.com 
 
Cells are grown in a base medium of RPMI-1640 plus the following supplements (to a final 
concentration): 10% Fetal Bovine Serum, 2mM L-Glutamine 
 
 
37.0°C, 5% CO2, 20% O2 
Next page or Protocols section at  http://www.cogcell.org/protocols.php 
95 hours 
Round, teardrop-shaded neuroblasts 
Adherent and suspended cells, grow mostly in clumps 
 
COGcell.org has a post-treatment cell line available from this same patient (SMS-KANR) 
 
 
 
 
All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO.  Each vial label 
contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen.  All 
cell lines are validated with original patient sample by STR analysis. 
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SMS-KANR Cell Line Data Sheet 
 
 
Cell Line Name:        SMS-KANR 
 
Disease: 
Phase of Therapy: 
Prior Therapy: 
Disease Stage: 
Source of Culture: 
Primary Tumor Site: 
Date Established: 
 
MYCN Status: 
p53 Status:  
TH expression: 
Karyotype: 
 
Modal No: 
 
IC90 (DIMSCAN*): 
*see reference 6 
 
 
 
Gender: 
Age: 
Race: 
 
STR Profile: 
 
Media Formulation: 
 
 
 
Growth Conditions: 
Subculturing: 
Doubling Time: 
Morphology: 
Growth Properties: 
 
Notes: 
 
 
 
Neuroblastoma 
Post-Chemotherapy (Progressive Disease) 
Cyclophosphamide, doxorubicin, radiation therapy 
4 
Bone marrow 
Pelvis 
October 1978 
 
Amplified 
  
Expressed 
del(1)(p21),del(19)(q13),del(4),del(11),del(17),t(4;10),t(17;18),t(11;?)(q23;?),t(13;?)(p11or13;?), 
inv(7)(p22q11.2),t(6;?)(q21or22;?),Monosomy (8,14,88,22),3 unidentified markers 
46 
 
 CBDCA (µg/ml)         CDDP (µg/ml)         DOX (ng/ml)         ETOP (ng/ml)         L-PAM (µg/ml) 
           1.3                             0.8               45.7               45.7    5.6 
 
CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan 
 
 
Female 
36 months 
 
 
On file at  http://strdb.cogcell.com 
 
Cells are grown in a base medium of RPMI-1640 plus the following supplements (to a final 
concentration): 10% Fetal Bovine Serum, 2mM L-Glutamine 
 
 
37.0°C, 5% CO2, 20% O2 
Next page or Protocols section at  http://www.cogcell.org/protocols.php 
69 hours 
Round, teardrop-shaded neuroblasts 
Adherent and suspended cells, grow mostly in clumps 
 
COGcell.org has a diagnosis (pre-therapy) cell line available from this same patient (SMS-KAN) 
 
 
 
All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO.  Each vial label 
contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen.  All 
cell lines are validated with original patient sample by STR analysis. 
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